Tomahawk, WI 05/25/2014 (Basicsmedia) – Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced its latest earnings data on May 8, 2014. The company notched up $0.23 earnings per share in the last quarter. Orexigen Therapeutics has carried out ground breaking scientific innovations in the realm of drugs for treating obesity related disorders.

Financial Estimates

Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s share prices are slowly gaining momentum. The stock has a 52 week low of 4.59 and a year long high of 7.84.  The stock has a 200 day average amounting to $6.10/share and $5/share over a 50 day period. The company has $664.23 million worth market capitalization. In April 2014, the company’s shares grew nearly 8.8%; hence, the short-interest staggered at 10.0 days.

Contrave – Awaiting Approvals For Sales Worldwide

The company is currently working on seeking approval for rolling out sales of Contrave – an anti obesity drug, across the U.S. and Europe. OREX expects decisions in this regard, towards the end of Q2-2014. Once the drug is approved by the regulatory body – FDA, Contrave will emerge as the third major entrant to the US market.

In the European market, Belviz (anti-obesity drug innovated and marketed by Arena) and Qsymia (a product from Vivus) have already faced criticism and rejection. Hence, if Contrave succeeds to notch up approval for sales across Europe, it will be the sole contender to evolve as the first prospective entrant to the European market.

About Contrave

Contrave (naltrexone SR or Bupropion SR) is a thoroughly investigated innovative medicine that evaluates the loss of weight and maintains the same. This drug passed varied clinical trials; the individuals upon whom the trials were focused, reported up to 5% or more over a duration of 12 months!

OREX And Its Rights

Orexigen Therapeutics, Inc. (NASDAQ:OREX) has reserved the rights to conduct sales of Contrave across North American territories to Takeda Pharmaceuticals. The company is yet to partner with firms for distribution and sales rights across the world (except North America). On October 2013, OREX has submitted for marketing authorization for Contrave to the regulatory authority, European Medicines Agency.

The investors have reposed confidence; the stock that had its highs and lows are currently shooting upwards!

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.